

Specialty Quantity Limit Program

Lifyorli

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Lifyorli	relacorilant

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Lifyorli 150 mg carton (contains 9 100mg capsules and 18 25mg capsules)	27 capsules per 21 days
Lifyorli 125 mg carton (contains 9 100mg capsules and 9 25mg capsules)	18 capsules per 21 days

FDA-recommended Dosing

150 mg orally once on the day before, the day of, and the day after each nab-paclitaxel (Abraxane) infusion which is administered on days 1, 8, and 15 of each 28-day cycle

Dose reduction to 125 mg orally is recommended for the management of adverse reactions.

Reference number(s)
7428-H

References

1. Lifyorli [package insert]. Redwood City, CA: Corcept Therapeutics, Incorporated; March 2026.